ArticleScientific reports2025
Heat shock proteins related signature characterizes immune status and predicts prognosis of gliomas.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioma classification is crucial for effective diagnosis and treatment. Heat Shock Proteins (HSPs) have been associated with tumor development and progression. In this study, we established a prognostic model for glioma based on Heat Shock Proteins-associated genes (HSPGs). Using the Cancer Genome Atlas (TCGA) cohorts and the Chinese Glioma Genome Atlas (CGGA), we identified a signature of 4 HSPGs as an independent prognostic factor for glioma. The risk model demonstrated excellent performance in both training and validation sets. Additionally, we developed a nomogram incorporating clinical parameters and the HSPGs signature to enhance prognostic prediction. Immunoenrichment analysis revealed a correlation between the risk score and the immunosuppressive status of glioma. In the functional assays, HSPA5 was identified as a key participant in several critical biological processes associated with glioma. Silencing HSPA5 expression may lead to the inhibition of glioma cell proliferation, migration, invasion and resistance to apoptosis. These findings present a novel classification for glioma prognosis with enhanced accuracy and offer valuable insights into the potential use of HSPGs as prognostic indicators for gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.